|
1
|
Torelli GF, Chiaretti S, Peragine N, Barberi W, Santodonato L, D'Agostino G, Abruzzese E, Del Principe MI, Mancino A, Matarazzo M, Bafti MS, Mancini M, Messina M, Castiello L, Guarini A, Foà R. Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial. Am J Hematol 2022; 97:E204-E207. [PMID: 35315128 DOI: 10.1002/ajh.26537] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Revised: 03/09/2022] [Accepted: 03/11/2022] [Indexed: 11/10/2022]
Affiliation(s)
- Giovanni Fernando Torelli
- Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University Rome Italy
| | - Sabina Chiaretti
- Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University Rome Italy
| | - Nadia Peragine
- Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University Rome Italy
| | - Walter Barberi
- Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University Rome Italy
| | | | | | | | | | | | - Mabel Matarazzo
- Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University Rome Italy
| | - Mahnaz Shafii Bafti
- Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University Rome Italy
| | - Marco Mancini
- Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University Rome Italy
| | | | | | - Anna Guarini
- Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University Rome Italy
| | - Robin Foà
- Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I Sapienza University Rome Italy
| |
Collapse
|
|
2
|
Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. Blood 2021; 138:2290-2293. [PMID: 34297829 DOI: 10.1182/blood.2021011822] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 07/04/2021] [Indexed: 11/20/2022] Open
|